VUMON (teniposide injection) is a cytotoxic drug which should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available.
Severe myelosuppression with resulting infection or bleeding may occur. Hypersensitivity reactions, including anaphylaxis-like symptoms, may occur with initial dosing or at repeated exposure to VUMON. Epinephrine, with or without corticosteroids and antihistamines, has been employed to alleviate hypersensitivity reaction symptoms.
Teniposide is a semisynthetic derivative of podophyllotoxin.
VUMON® (teniposide injection) (also commonly known as VM-26), is supplied as a sterile nonpyrogenic solution in a nonaqueous medium intended for dilution with a suitable parenteral vehicle prior to intravenous infusion.
VUMON, in combination with other approved anticancer agents, is indicated for induction therapy in patients with refractory childhood acute lymphoblastic leukemia.
Published Studies Related to Vumon (Teniposide)
Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. [2003.09.01]
PURPOSE: The role of chemotherapy in the primary treatment of malignant glioma remains controversial. The results from the German-Austrian Glioma trial (GAG, 1983 to 1988) demonstrated a survival benefit for chemotherapy using carmustine (BCNU) plus teniposide (VM26) over BCNU alone in addition to radiotherapy in patients with a Karnofsky performance score (KPS) more than 60. The Neuro-Oncology Working Group (NOA) of the German Cancer Society therefore compared the efficacy of nimustine (ACNU) plus VM26 and ACNU plus cytarabine (Ara-C) chemotherapy in addition to standard radiotherapy in patients with newly diagnosed malignant glioma... CONCLUSION: The median survival times and 2-year survival rates for patients with anaplastic glioma and glioblastoma achieved in the NOA-01 trial compare favorably with historical trials and with the Radiation Therapy Oncology Group database. The toxicity profile favors ACNU plus VM26 for further evaluation.
Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588). [2002.09]
This randomized study of previously untreated patients with extensive disease small cell lung cancer was designed (a) to compare the survival of patients treated with either effective standard chemotherapy or an investigational anti-cancer drug as initial therapy and (b) to evaluate response rates and toxic effects of such therapies...
Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. [2000.10.01]
PURPOSE: Approximately 60% of patients with small-cell lung cancer (SCLC) develop brain metastases. Whole-brain radiotherapy (WBRT) gives symptomatic improvement in more than 50% of these patients. Because brain metastases are a sign of systemic progression, and chemotherapy was found to be effective as well, it becomes questionable whether WBRT is the only appropriate therapy in this situation... CONCLUSION: Adding WBRT to teniposide results in a much higher response rate of brain metastases and in a longer time to progression of brain metastases than teniposide alone. Survival was poor in both groups and not significantly different.
The cost-effectiveness of paclitaxel (Taxol) + cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer: a multicountry analysis. [1999.07]
A large randomized clinical trial in advanced, previously untreated, non-small cell lung cancer (NSCLC) patients revealed better response rates and better tolerance for paclitaxel+cisplatin (TAXCIS) compared to teniposide+cisplatin (TENCIS). Since economic evidence is receiving increasing attention in health care, we conducted an economic evaluation based on the trial results in The Netherlands, Belgium, France and Spain...
Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. [1998.06]
PURPOSE: To compare two cisplatin based chemotherapy schedules in patients with advanced non-small-cell lung cancer (NSCLC)... CONCLUSION: Although survival was not improved, arm B offers a better palliation for advanced NSCLC patients than arm A.
Clinical Trials Related to Vumon (Teniposide)
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma [Recruiting]
The overall objective of this protocol is to improve the cure rate of relapsed precursor
B-cell acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma.
This phase II trial is studying risk-directed therapy for B-lymphoblastic leukemia or
lymphoma in first relapse. Standard risk (SR) and high risk (HR) participants will receive
different therapy. Treatment will consist of chemotherapy for SR participants, and
chemotherapy followed by hematopoietic stem cell transplant (HSCT) for HR in first relapse.
Induction therapy consists of three blocks of chemotherapy. The first block is a novel
immunotherapy regimen that includes chemotherapy, rituximab and infusion of haploidentical
natural killer (NK) cells. SR participants will continue to receive chemotherapy for a total
duration of approximately 2 years. HR participants will be candidates for HSCT and will
proceed to transplant once a suitable donor is found and their minimal residual disease
(MRD) is negative.
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia [Recruiting]
The main purpose of this study is to find out how well participants with relapsed or
refractory ALL respond to treatment with an etoposide- and teniposide-based induction
chemotherapy regimen and what the side effects are.
Treatment of High Risk Adult Acute Lymphoblastic Leukemia [Recruiting]
Current therapeutic protocols for adult ALL consider MRD together with the baseline risk
factors (age, WBC count, immunophenotype, cytogenetics) and speed in response to therapy for
treatment decisions. On the other hand, the systematic use of allogeneic SCT for all adult
patients (pts) with Ph- HR-ALL is still a matter of debate. The aim of the prospective study
ALL-AR-03 from the Spanish PETHEMA Group was to evaluate the response to a differentiated
therapy (chemotherapy or allogeneic SCT) according to early bone marrow blast clearance and
MRD levels (assessed by cytofluorometry at the end of induction and consolidation therapy)
in HR Ph- adult ALL patients.
Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia [Recruiting]
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Giving more than one
drug (combination chemotherapy) may kill more cancer cells. It is not yet known which
combination chemotherapy regimen is more effective in treating acute lymphoblastic leukemia.
PURPOSE: This randomized phase III trial is studying different combination chemotherapy
regimens to compare how well they work in treating young patients with acute lymphoblastic
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) [Recruiting]
The study evaluates the efficacy and tolerability of an intensified induction and
consolidation therapy. Thereafter patients receive individualised treatment stratified
according to relapse risk with stem cell transplantation for patients with high and very
high risk of relapse. Patients with standard risk receive further consolidation and
reinduction chemotherapy. In parallel minimal residual disease (MRD) is evaluated. After six
months and one year the decision on intensification or discontinuation of therapy is made
based on the results of MRD evaluation.